Coronary Artery Disease Global Market Report 2024

The coronary artery disease market size has grown rapidly in recent years. It will grow from $26.3 billion in 2023 to $28.97 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The observed growth in the historic period can be attributed to several factors. These include the widespread prevalence of coronary artery disease, advancements in minimally invasive surgical techniques contributing to improved treatment options, the rise in sedentary lifestyles impacting cardiovascular health, an aging population leading to increased cases of coronary artery disease, and the evolution and advancement of pharmacological treatments providing better management and care for individuals affected by this condition.

The coronary artery disease market size is expected to see rapid growth in the next few years. It will grow to $42.65 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. The anticipated growth in the forecast period can be attributed to several factors, including the increasing impact of lifestyle-related factors on heart health, a heightened focus on telemedicine and remote monitoring for managing coronary artery disease, the expansion of interventional cardiology procedures for improved treatment outcomes, a shift towards value-based healthcare models emphasizing patient outcomes, and the ongoing development of innovative drug therapies for more effective management of the condition. Major trends expected in this forecast period encompass the development of gene therapies targeting heart-related conditions, the integration of artificial intelligence in diagnosing and managing coronary artery disease, a heightened focus on mental health aspects within coronary artery disease care, a rise in home-based healthcare services catering to cardiac patients, and the adoption of remote cardiac rehabilitation programs for enhanced patient recovery and management.

The growth of the coronary artery disease market is anticipated to be fueled by the increasing prevalence of coronary artery disease (CAD). This medical condition is characterized by the narrowing or blockage of coronary arteries, responsible for supplying blood to the heart muscle. Factors contributing to the rise in CAD cases include dietary changes, stress, sedentary lifestyle, obesity, and aging. Treatment modalities for coronary artery disease involve drug interventions such as clopidogrel, ticagrelor, warfarin, and heparin, along with procedural approaches such as coronary artery bypass grafting, angioplasty, and stenting. As per the Centers for Disease Control and Prevention's May 2023 report, coronary heart disease, the most common form of heart disease, claimed 375,476 lives in 2021, affecting approximately 5% of adults aged 20 and above. This prevalence is expected to drive the coronary artery disease market during the forecast period.

The growth trajectory of the coronary artery disease market is further propelled by the rising aging population. An aging population signifies a demographic shift characterized by an increasing proportion of elderly individuals within a society. The demographic trend contributes significantly to the expansion of the coronary artery disease market, given the higher susceptibility of older individuals to this condition. According to the World Health Organization's October 2022 projection, by 2030, one in six individuals globally will be 60 years old or older. During this period, the population aged 60 and over is expected to increase from 1 billion in 2020 to 1.4 billion. Looking ahead to 2050, the global population of individuals aged 60 and older is forecasted to double, reaching 2.1 billion. This demographic shift underlines the role of the rising aging population in propelling the coronary artery disease market.

Prominent companies within the coronary artery disease market are directing their efforts toward developing cutting-edge technologies, including AI-based blood tests. These tests leverage artificial intelligence (AI) algorithms for the analysis and interpretation of blood-related data. For instance, in February 2023, Cardio Diagnostics Holdings, a US-based company specializing in AI-based integrated genetic-epigenetic engines, introduced PrecisionCHD. This innovative blood test combines genetic and epigenetic analyses to enable early identification of coronary heart disease. With a sensitivity of over 75% for both men and women, PrecisionCHD employs a machine-learning model derived from the analysis of billions of genomic and epigenomic data points, incorporating epigenetic (DNA methylation) and genetic (single nucleotide polymorphism) biomarkers.

Major players in the coronary artery disease market are concentrating on the development of groundbreaking products such as drug-coated balloon catheters. These medical devices are utilized in interventional cardiology procedures to address narrowed or blocked blood vessels, particularly in cases of coronary artery disease or peripheral artery disease. An example is Medtronic PLC, an Ireland-based medical device company, which launched Prevail DCB, the latest-generation drug-coated balloon catheter, in July 2021. Prevail DCB is employed in percutaneous coronary intervention (PCI) procedures to address the narrowing or obstruction of coronary arteries in individuals diagnosed with coronary artery disease (CAD). This emphasis on innovation underscores the commitment of major industry players to advancing technologies for enhanced coronary artery disease management.

In April 2023, Abbott Laboratories, a prominent US-based medical devices and healthcare company, completed the acquisition of Cardiovascular Systems Inc. for a total consideration of $890 million. This strategic acquisition is designed to enhance Abbott's capabilities in addressing vascular disease by integrating the innovative solutions developed and commercialized by Cardiovascular Systems Inc. The latter, based in the United States, is a medical device company with a focus on creating and bringing to market advanced treatments for peripheral and coronary artery disease. This move is indicative of Abbott's commitment to expanding its portfolio and strengthening its position in the medical devices sector, particularly in the field of cardiovascular health.

Major companies operating in the coronary artery disease market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Gilead Sciences Inc., Amgen Inc. , Viatris Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Lupin Pharmaceuticals Inc., Wockhardt Ltd., Honya Medical Inc., Idorsia Pharmaceuticals Ltd., Cytokinetics Inc., Kowa Pharmaceuticals America Inc., Sinotau Pharmaceutical Group, HRV Global Life Sciences, Barr Pharmaceuticals Inc., AdvanceCor GmbH, Deutsches Zentrum für Herz- Kreislauf-Forschung (DZHK) e.V.

North America was the largest region in the coronary artery disease market in 2023. The regions covered in the coronary artery disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the coronary artery disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Primary treatments for coronary artery disease encompass various approaches such as medication, surgical interventions, additional therapies, and other related strategies. Medications include pharmaceutical substances such as clopidogrel, atorvastatin, metoprolol, lisinopril, losartan, amlodipine, nitroglycerin, among others. Diagnosis involves medical procedures such as electrocardiogram (ECG), echocardiogram, stress tests, cardiac catheterization, heart CT scans, and other diagnostic methods. These medications and diagnostic procedures are made available through diverse distribution channels such as hospital pharmacies, retail pharmacies, online pharmacy platforms, and others. The utilization of these treatments and diagnostic measures extends to hospitals, specialty clinics, and other healthcare facilities.

The coronary artery disease market research report is one of a series of new reports that provides coronary artery disease market statistics, including coronary artery disease industry global market size, regional shares, competitors with a coronary artery disease market share, detailed coronary artery disease market segments, market trends and opportunities, and any further data you may need to thrive in the coronary artery disease industry. This coronary artery disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The coronary artery disease market includes revenues earned by entities by providing coronary angioplasty, coronary artery bypass and heart transplant services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.